In the EU, the government will set the price. One of the milestones is actually coming to agreement regarding pricing with the government. It will allow Titan/Molteni to get a solid single or double out of each sale.
In US, Braeburn tried for a grand slam home run on the price. No one purchased. It's hard to find a pharma company equipped to do buy and bill in addiction who is going to be interested in a single or double...they all want the home run.
News 
Market Data 
Discover 
AI
